LOGIN
ID
PW
MemberShip
2024-10-22 10:17
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Company
K-similars won record number of U.S.¡¤Europe nods this year
by
Chon, Seung-Hyun
Aug 27, 2024 05:50am
Korean biopharmaceutical companies have launched the highest number of biosimilars in history this year in the United States and European markets. As Celltrion and Samsung Bioepis won approvals for six biosimilars over eight months in the world's largest market, they topped the previous record of five cases of five years ago. According to sou
Company
More urothelial cancer drug options now available in KOR
by
Hwang, Byung-woo
Aug 26, 2024 05:46am
A number of immuno-oncology and antibody-drug conjugate (ADC) drugs are being granted approval as a first-line treatment of urothelial cancer, increasing the treatment options that had previously been dominated by platinum-based chemotherapy. Although they are not yet reimbursed and have yet to become mainstream treatment options, it is expe
Company
¡®Lilly will reapply for Retevmo¡¯s reimbursement in Korea¡¯
by
Eo, Yun-Ho
Aug 26, 2024 05:46am
¡°We will do our best to receive reimbursement for Retevmo in Korea. However, the will of the health authorities is as important¡± The company has expressed its will to list a RET-targeted therapy option in Korea. The question that remains now is when. Lilly's RET inhibitor Retevmo (selpercatinib) remains non-reimbursed since the compa
Company
Colorectal cancer drug Fruzaqla may be introduced in H2
by
Eo, Yun-Ho
Aug 26, 2024 05:46am
A new treatment option is expected to emerge in the field of colorectal cancer later this year. According to industry sources, the final review is underway for the approval of Fruzaqla (fruquintinib), which was designated as a Global Innovative products on Fast Track (GIFT) by the Ministry of Food and Drug Safety in November last year.
Company
Expansion of newly launched Kerendia underway in KOR
by
Moon, sung-ho
Aug 23, 2024 06:18am
Since early this year, Kerendia has been covered by reimbursement in clinical practices in South Korea. Kerendia's indication may expand to hypertension as it becomes available for prescriptions at clinical practices. According to the pharmaceutical industry on August 13th, Kerendia (finerenone) is now being used in clinical practices
Company
Will the SGLT-2i Jardiance be reimb for CKD in 2H?
by
Eo, Yun-Ho
Aug 23, 2024 06:18am
Attention is focused on whether the SGLT-2 inhibitor Jardiance can settle as a reimbursed prescription option for chronic kidney disease in the second half of the year. According to industry sources, the Health Insurance Review and Assessment Service is currently reviewing the reimbursement expansion of Boehringer Ingelheim and Lilly Kore
Company
Yungjin applies for approval of its Ofev generic
by
Hwang, Byung-woo
Aug 23, 2024 06:17am
Yungjin Pharmaceutical announced on the 22nd that it has completed the license application for a generic version of Boehringer Ingelheim's ¡®Ofev Soft Cap (Ofev)¡¯ that it had developed by changing the original drug¡¯s soft capsule formulation into a tablet. As a global blockbuster product, Ofev (nintedanib) is widely used in combination
Company
Yuhan¡¯s Leclaza enters US 6yrs after signing licensing deal
by
Chon, Seung-Hyun
Aug 22, 2024 05:50am
Yuhan Corp¡¯s new anticancer drug Leclaza has successfully entered the U.S. market. The drug has reached the commercialization stage 6 years after licensing out its technology to Janssen. As a result, the company will receive USD 60 million as a milestone payment with Leclaza¡¯s approval in the U.S. The company has earned nearly KRW 300 billion
Company
Bavencio shows clear benefit in urothelial cancer
by
Hwang, Byung-woo
Aug 22, 2024 05:50am
The treatment landscape for metastatic urothelial cell carcinoma has changed after Bavencio (avelumab) was granted reimbursement as a first-line maintenance therapy in Korea. Bavencio addressed the high unmet need that had remained for a maintenance therapy option on site, rapidly changing the prescribing pattern. Merck Biopharma Korea
Company
MET-targeting anticancer drug 'Tepmetko' prescribed at Big 5
by
Eo, Yun-Ho
Aug 22, 2024 05:50am
The MET-targeting anticancer drug 'Tepmetko' is now available for prescription at general hospitals. Sources said that Merck Korea's Tepmetko (tepotinib), a treatment for patients with topically advanced or metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping mutat
<
11
12
13
14
15
16
17
18
19
20
>